PE20210132A1 - Anticuerpos anti-cd3 y usos de estos - Google Patents
Anticuerpos anti-cd3 y usos de estosInfo
- Publication number
- PE20210132A1 PE20210132A1 PE2020001886A PE2020001886A PE20210132A1 PE 20210132 A1 PE20210132 A1 PE 20210132A1 PE 2020001886 A PE2020001886 A PE 2020001886A PE 2020001886 A PE2020001886 A PE 2020001886A PE 20210132 A1 PE20210132 A1 PE 20210132A1
- Authority
- PE
- Peru
- Prior art keywords
- sec
- heavy chain
- light chain
- understands
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676081P | 2018-05-24 | 2018-05-24 | |
| PCT/IB2019/054188 WO2019224717A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210132A1 true PE20210132A1 (es) | 2021-01-19 |
Family
ID=67211773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001886A PE20210132A1 (es) | 2018-05-24 | 2019-05-21 | Anticuerpos anti-cd3 y usos de estos |
Country Status (38)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP2021524255A (ja) | 2018-05-24 | 2021-09-13 | ヤンセン バイオテツク，インコーポレーテツド | 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 |
| MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020018825A1 (en) | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with bcma specificity and uses thereof |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| CA3147735A1 (en) | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| TW202146449A (zh) * | 2019-12-18 | 2021-12-16 | 美商健生生物科技公司 | 用於體內生物靶向之材料及方法 |
| KR20220147631A (ko) * | 2020-02-27 | 2022-11-03 | 얀센 바이오테크 인코포레이티드 | 면역 반응을 조절하기 위한 물질 및 방법 |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| JP2023528350A (ja) | 2020-05-27 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用 |
| AU2021317111A1 (en) | 2020-07-29 | 2023-03-30 | Janssen Biotech, Inc. | Proteins comprising HLA-G antigen binding domains and their uses |
| WO2022049220A2 (en) * | 2020-09-02 | 2022-03-10 | Genmab A/S | Antibody therapy |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| JP2023543826A (ja) * | 2020-09-29 | 2023-10-18 | イノベント バイオロジクス（シンガポール）プライベート リミティド | 抗ｃｄ３抗体およびその使用 |
| TW202233672A (zh) | 2020-10-22 | 2022-09-01 | 美商健生生物科技公司 | 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途 |
| TW202302636A (zh) * | 2021-02-16 | 2023-01-16 | 比利時商健生藥品公司 | 靶向ｂｃｍａ、ｇｐｒｃ５ｄ及ｃｄ３之三特異性抗體 |
| US20220411517A1 (en) | 2021-05-21 | 2022-12-29 | Leo Pharma A/S | IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof |
| PE20240727A1 (es) * | 2021-08-27 | 2024-04-15 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos |
| US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
| US20250346668A1 (en) * | 2022-03-25 | 2025-11-13 | Genor Biopharma Co., Ltd | Cd3-targeting antibody and use thereof |
| WO2024062074A1 (en) * | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| AU2023356984A1 (en) | 2022-10-05 | 2025-03-20 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2024126833A1 (en) * | 2022-12-16 | 2024-06-20 | Ichnos Sciences SA | Cd47-il1rap bispecific antibodies |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| US20250313641A1 (en) | 2024-04-09 | 2025-10-09 | Amgen Inc. | Agonistic anti-il-2rbg heavy-chain antibodies |
| WO2025230233A1 (ko) * | 2024-05-03 | 2025-11-06 | 국민대학교산학협력단 | 인간 cd3에 특이적인 항체 및 이의 용도 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| DE69830065T2 (de) | 1997-09-16 | 2006-01-19 | Egea Biosciences, LLC, San Diego | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| PL3653049T3 (pl) | 2012-12-14 | 2024-02-26 | Omniab, Inc. | Polinukleotydy kodujące przeciwciała gryzoni z ludzkimi idiotypami i zwierzęta je zawierające |
| ES2776706T3 (es) * | 2013-07-05 | 2020-07-31 | Genmab As | Anticuerpos contra CD3 humanizados o quiméricos |
| CN112390883A (zh) * | 2013-12-17 | 2021-02-23 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| AU2015266077A1 (en) | 2014-05-28 | 2016-09-29 | F. Hoffmann-La Roche Ag | Antibodies binding to human and cynomolgus CD3 epsilon |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| JP2018534933A (ja) | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
| CN114395048B (zh) | 2016-09-14 | 2025-01-28 | 特纳奥尼股份有限公司 | Cd3结合抗体 |
| JOP20200292A1 (ar) * | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
| JP2021524255A (ja) * | 2018-05-24 | 2021-09-13 | ヤンセン バイオテツク，インコーポレーテツド | 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 |
| MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
-
2019
- 2019-05-21 SM SM20250221T patent/SMT202500221T1/it unknown
- 2019-05-21 US US16/418,082 patent/US11603405B2/en active Active
- 2019-05-21 HR HRP20250621TT patent/HRP20250621T1/hr unknown
- 2019-05-21 KR KR1020207037046A patent/KR20210012007A/ko active Pending
- 2019-05-21 LT LTEPPCT/IB2019/054188T patent/LT3802608T/lt unknown
- 2019-05-21 CN CN201980049271.7A patent/CN112912397B/zh active Active
- 2019-05-21 JP JP2020565282A patent/JP7530299B2/ja active Active
- 2019-05-21 CR CR20200568A patent/CR20200568A/es unknown
- 2019-05-21 EA EA202092847A patent/EA202092847A1/ru unknown
- 2019-05-21 EP EP25173398.6A patent/EP4643951A2/en active Pending
- 2019-05-21 MA MA52773A patent/MA52773B1/fr unknown
- 2019-05-21 MX MX2020012587A patent/MX420253B/es unknown
- 2019-05-21 HU HUE19737219A patent/HUE072251T2/hu unknown
- 2019-05-21 PT PT197372196T patent/PT3802608T/pt unknown
- 2019-05-21 UA UAA202008271A patent/UA129050C2/uk unknown
- 2019-05-21 DK DK19737219.6T patent/DK3802608T3/da active
- 2019-05-21 FI FIEP19737219.6T patent/FI3802608T3/fi active
- 2019-05-21 SI SI201930938T patent/SI3802608T1/sl unknown
- 2019-05-21 EP EP19737219.6A patent/EP3802608B1/en active Active
- 2019-05-21 PE PE2020001886A patent/PE20210132A1/es unknown
- 2019-05-21 AU AU2019274656A patent/AU2019274656A1/en active Pending
- 2019-05-21 RS RS20250579A patent/RS66901B1/sr unknown
- 2019-05-21 BR BR112020023508-3A patent/BR112020023508A2/pt unknown
- 2019-05-21 JO JOP/2020/0302A patent/JOP20200302A1/ar unknown
- 2019-05-21 WO PCT/IB2019/054188 patent/WO2019224717A2/en not_active Ceased
- 2019-05-21 ES ES19737219T patent/ES3032856T3/es active Active
- 2019-05-21 CA CA3101271A patent/CA3101271A1/en active Pending
- 2019-05-21 PL PL19737219.6T patent/PL3802608T3/pl unknown
- 2019-05-21 SG SG11202011270QA patent/SG11202011270QA/en unknown
- 2019-05-21 CN CN202510209510.8A patent/CN120058941A/zh active Pending
- 2019-05-24 TW TW108118086A patent/TW202012443A/zh unknown
- 2019-05-24 AR ARP190101400A patent/AR115422A1/es unknown
- 2019-05-24 UY UY0001038245A patent/UY38245A/es unknown
-
2020
- 2020-11-09 PH PH12020551920A patent/PH12020551920A1/en unknown
- 2020-11-19 IL IL278846A patent/IL278846A/en unknown
- 2020-11-23 CO CONC2020/0014506A patent/CO2020014506A2/es unknown
- 2020-11-23 EC ECSENADI202075215A patent/ECSP20075215A/es unknown
- 2020-11-23 CL CL2020003033A patent/CL2020003033A1/es unknown
- 2020-11-23 NI NI202000089A patent/NI202000089A/es unknown
- 2020-11-24 SA SA520420631A patent/SA520420631B1/ar unknown
-
2023
- 2023-03-08 US US18/180,225 patent/US20230322924A1/en active Granted
-
2024
- 2024-05-29 JP JP2024087232A patent/JP2024116190A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20230389A1 (es) | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso |